Skip to content

Stryker Agrees to Sell Spinal Implants Business

Stryker, one of the world’s largest medtech companies, recently announced an agreement to sell its Spinal Implants business to Viscogliosi Brothers, a New York-based, family-owned investment firm founded by three brothers.

According to the press release, Viscogliosi Brothers will create a new company, VB Spine, to manage the spinal implants business.  The sale is expected to close by mid-2025.

Stryker plans to partner with VB Spine going forward.  Kevin Lobo, Stryker’s CEO, stated during a recent earnings call: “[W]e will be providing the enabling tech.  They will be providing the implants.”  The enabling tech includes exclusive access to Stryker’s CoPilot and Mako Spine product lines.

When asked why it was the right time for the divestment, Kevin Lobo explained:

We’ve moved into so many other faster growing spaces, and this is really where we’d like to spend our time and our energy. It’s a very competitive market on the implant side of the business where we just haven’t had the same degree of innovation that we’ve had in other parts of our portfolio. So this felt like the right time.

Regarding the sale, the Viscogliosi Brothers commented: “We see a tremendous opportunity to provide the focus, surgeon-centric innovation, and commercial execution needed to grow the business and further impact patient lives and outcomes.”

The press release states that the Viscogliosi Brothers have led the transformation of multiple businesses in the spine industry specifically including: Spine Solutions, Spine Next, Paradigm Spine, Simplify Medical, Centinel Spine, Companion Spine, Spine BioPharma and Woven Orthopedics Technologies, among others.

The sale of Stryker’s Spinal Implants business comes on the heels of Stryker’s expansion into the peripheral vascular market, with its recent acquisition of Inari Medical in early 2025.  Stryker had a busy year in 2024, with 7 acquisitions in a variety of technology sectors.

When asked about Stryker’s prioritized list of current focus areas for M & A during the Q4 2024 earnings call, Kevin Lobo stated that Stryker will continue to look within the peripheral vascular space for follow-on acquisitions and also mentioned the urology, neuromodulation, soft tissue robots, and health care IT spaces.  However, he commented that Stryker will likely not make a jump into the cardiovascular segment in the near term.

 

Tags

, , , , , , , , ,

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal